The global high-throughput genomic screening for preventive healthcare market size was estimated at USD 846.05 million in 2025 and is projected to reach USD 2,169.74 million by 2033, growing at a CAGR of 12.6% from 2026 to 2033.The market is experiencing significant growth as healthcare systems increasingly shift from reactive treatment approaches to personalized prevention strategies supported by preventive and precision medicine. This transition reflects a broader emphasis on identifying genetic predispositions to diseases at an early stage, enabling healthcare providers and individuals to implement targeted interventions, lifestyle modifications, and monitoring programs before symptoms develop. As a result, high-throughput genomic screening is becoming an essential tool in modern healthcare for improving long-term outcomes and reducing the burden of chronic and hereditary conditions.
Advancements in high-throughput genomic technologies are further accelerating market expansion by enabling faster, more scalable, and highly accurate genetic analysis. Innovations in next-generation sequencing, bioinformatics, automation, and data interpretation are allowing laboratories to process large volumes of genomic data efficiently while maintaining high levels of precision and reproducibility. These technological improvements are expanding the accessibility and clinical utility of genomic screening programs across hospitals, diagnostic laboratories, and public health initiatives.
For instance, in 2025, BGI Genomics and the Thalassemia International Federation highlighted that high-throughput sequencing improved the accuracy of carrier and at-risk couple identification in thalassemia prevention programs. This advancement demonstrates the growing role of genomic screening in large-scale preventive healthcare initiatives by enabling precise and efficient identification of individuals with inherited genetic risks. By supporting scalable and accurate genetic risk assessments, such developments strengthen the preventive healthcare paradigm and contribute significantly to the continued expansion of the high-throughput genomic screening market for preventive healthcare.
Key Market Trends & Insights
• North America dominated the high-throughput genomic screening for preventive healthcare market and accounted for a 51.26% share in 2025. The region’s leading position is supported by its advanced healthcare infrastructure, strong adoption of precision medicine, substantial investments in genomic research, and the presence of major biotechnology and diagnostic companies. In addition, favorable reimbursement frameworks, growing awareness of preventive healthcare, and expanding use of genomic screening in clinical and public health programs continue to strengthen market growth across North America.
• The U.S. led the North American market and held the largest revenue share in 2025. The country’s dominance is driven by extensive implementation of next-generation sequencing technologies, robust research and development activity, and increasing integration of genomic testing into routine preventive care. Strong support from healthcare providers, academic institutions, and public health organizations has accelerated the adoption of high-throughput genomic screening for early disease detection and personalized risk assessment.
• By test type, the non-invasive prenatal testing (NIPT) segment held the largest market share of 30.48% in 2025. This segment’s leadership is attributed to the growing use of NIPT for early detection of chromosomal abnormalities and inherited genetic conditions during pregnancy. Its high accuracy, non-invasive nature, and increasing acceptance among healthcare providers and expectant parents have contributed significantly to widespread adoption.
• By technology, the next-generation sequencing (NGS) segment dominated the market with a share of 42.29% in 2025. NGS technology enables rapid, scalable, and highly accurate analysis of large volumes of genetic data, making it a cornerstone of preventive genomic screening. Ongoing improvements in sequencing speed, cost efficiency, and bioinformatics capabilities continue to expand its use across a broad range of healthcare applications.
• By application, the reproductive health & fertility segment captured the largest revenue share of 27.94% in 2025. The segment’s strong position is driven by increasing demand for carrier screening, fertility assessments, embryo testing, and prenatal genetic evaluations. These applications play a critical role in helping individuals and couples make informed reproductive decisions and identify potential genetic risks at an early stage.
Looking for more specific insights? Customize this report to suite your business needs
Key High-Throughput Genomic Screening for Preventive Healthcare Company Insights
The global high-throughput genomic screening for preventive healthcare industry is highly competitive, with numerous companies striving to maintain leadership through continuous innovation, test development, strategic collaborations, and geographic expansion. Leading participants offer extensive genomic testing portfolios, large-scale sequencing capabilities, and well-established distribution networks that serve both clinical and direct-to-consumer markets. These companies provide a broad range of solutions, including carrier screening, non-invasive prenatal testing, hereditary disease risk assessments, and population-based genomic programs designed to support early detection and preventive healthcare strategies.
Their expertise in securing regulatory approvals, integrating advanced bioinformatics, and operating high-throughput sequencing platforms enables them to deliver reliable, scalable, and clinically actionable results. By combining sequencing technologies with sophisticated data analysis tools, these organizations help healthcare providers and consumers interpret complex genetic information more effectively. Their strong operational infrastructure and technical capabilities allow them to process large sample volumes efficiently while maintaining high standards of quality and accuracy.
To remain competitive, many industry leaders are making substantial investments in research and development to introduce advanced preventive genomic screening solutions, including multi-gene panels, population-level sequencing initiatives, and artificial intelligence-powered interpretation platforms. These innovations are expanding the scope and accessibility of genomic testing while improving the precision and usefulness of genetic insights for preventive care.
Strategic partnerships and collaborations are also a common growth strategy in the industry. For instance, in 2025, Illumina partnered with MyOme to support clinical trials demonstrating the clinical impact and cost benefits of early genomic screening and integrated preventive care. This collaboration highlights the increasing focus on generating real-world evidence to validate the value of genomic screening in reducing healthcare costs and improving patient outcomes. Such partnerships are expected to play a critical role in accelerating adoption and advancing the integration of genomic technologies into mainstream preventive healthcare.
Key High throughput Genomic Screening For The Preventive Healthcare Companies:
The following key companies have been profiled for this study on the high-throughput genomic screening for preventive healthcare market.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• BGI Genomics
• 10x Genomics
• Pacific Biosciences
• Natera, Inc.
• Myriad Genetics, Inc.
• Fulgent Genetics
• Exact Sciences Corporation
• 23andMe
• Color Health, Inc
Grand View Research offers
√ Focused market intelligence reports on specific geographies or high-growth segments.
√ Extended forecast timelines for long-term planning.
√ Competitor Benchmarking and Supply Chain Analysis
√ Inclusion of regulatory and policy assessments.
√ Inclusion of custom data models, KPIs, or applications unique to your business
√ Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)